AllAnalyst Report
logoArgus•February 28, 2024

IQVIA Holdings Inc.: Raising target to $300 from $260

Symbols
IQV
Sector(s)
Healthcare
Rating
Current Price
$234.88
Price Target
Earnings Estimate
Summary

IQVIA Holdings is the world's largest provider of biopharmaceutical development services and commercial outsourcing services. The company is the result of the 2016 merger of Quintiles Transnational, a contract research organization, and IMS Health, a healthcare data and analytics provider. IQVIA is headquartered in Research Triangle Park, North Carolina. IQVIA provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. IQVIA provides intelligent connections across all aspects of healthcare through its analytics, technology, big data resources and extensive domain expertise. IQVIA's Connected Intelligence delivers actionable insights to enable customers to accelerate the clinical development and commercialization of new therapie

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Upgrade

Actions

Download Full Report

Related Reports

View more related reports

Analyst Profile

David H. Toung

Senior Analyst: Medical Devices & Healthcare Services
David covers the Pharmaceutical, Medical Devices, and Healthcare services sectors for Argus. He has more than two decades of experience in the financial analysis industry, having worked for McDonald & Co., JPMorgan Chase and Standard & Poor's, among others. His commentary has appeared on CNBC and in The New York Times. Prior to his financial career, David was a private practice attorney in New Jersey, and served as a Judicial Clerk for an Appellate Division judge in the New Jersey Superior Court. David has a law degree from Rutgers University, where he was a member of the Law Review. He has a B.A. degree in Government from Cornell University. He has passed Level II of the Chartered Financial Analyst examination.